Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment

BACKGROUND: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are currently not available or planned. AIM: To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective regist...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Aliment Pharmacol Ther
Main Authors: Biemans, Vince B. C., van der Woude, C. Janneke, Dijkstra, Gerard, van der Meulen‐de Jong, Andrea E., Löwenberg, Mark, de Boer, Nanne K., Oldenburg, Bas, Srivastava, Nidhi, Jansen, Jeroen M., Bodelier, Alexander G. L., West, Rachel L., de Vries, Annemarie C., Haans, Jeoffrey J. L., de Jong, Dirk, Hoentjen, Frank, Pierik, Marieke J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318204/
https://ncbi.nlm.nih.gov/pubmed/32441396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15745
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados